ManilaMed · September 2026 · Demo Data
Revenue — Month to Date
₱26.35M
-5.9% vs. target
vs. Target
₱1.65M
Below plan
Avg Daily Revenue
₱2.63M
Target: ₱933K/day
Projected Month-End
₱79.04M
10/30 days elapsed
Daily actual vs. target — September 2026
Actual vs. target — ranked by revenue
Revenue vs. target by service line (₱K)
Revenue share by service line
Ranked by revenue · includes variance and revenue per patient
| Rank | Service Line | Revenue | Variance |
|---|---|---|---|
| 1 | Cardiology | ₱5.61M | ▲ 7.9% |
| 2 | Oncology | ₱4.88M | ▼ 12.9% |
| 3 | Surgery | ₱4.35M | ▼ 2.9% |
| 4 | OB-GYN | ₱3.27M | ▼ 6.7% |
| 5 | Orthopedics | ₱3.08M | ▲ 10.1% |
| 6 | Neurology | ₱2.45M | ▼ 2.7% |
| 7 | Pediatrics | ₱1.63M | ▼ 31.3% |
| 8 | Emergency | ₱1.08M | ▼ 29.2% |
AI-generated analysis — Month to Date · demo data only
MTD at -5.9% vs. plan through Day 10
₱26.35M of ₱28.00M MTD target captured. At current pace, September month-end projects to ₱79.04M (-5.9% vs. monthly target).
Pediatrics is the highest-risk service line at -31.3% vs. target
₱-746K shortfall. Rev/patient of ₱30K vs. prior ₱30K. Recommend department head review.
Orthopedics leads at +10.1% above target
₱3.08M revenue from 32 patients. Rev/patient of ₱96K improving vs. prior period.
Top 3 service lines account for 56% of revenue
Cardiology, Oncology, Surgery collectively drive the majority of revenue. Moderate concentration risk; monitor for volume shifts in these departments.